Target engagement biomarkers for pain receptors KU Leuven
The clinical development of novel analgesics is facing extreme challenges. The highest attrition is caused in the proof-of-concept phase (phase II) due to lack of efficacy and/or safety in the target population. Lack of efficacy is most prominent in CNS related diseases, including chronic pain conditions, in which animal models of efficacy often are insufficient to predict target engagement and efficacy in patients. A potential approach for ...